A A Hurwitz

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma
    A A Hurwitz
    Howard Hughes Medical Institute, Cancer Research Laboratory, University of California, Berkeley 94720, USA
    Int J Cancer 77:107-13. 1998
  2. pmc CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
    A A Hurwitz
    Howard Hughes Medical Institute, Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA
    Proc Natl Acad Sci U S A 95:10067-71. 1998
  3. ncbi request reprint Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis
    A A Hurwitz
    Department of Molecular and Cellular Biology, University of California, Berkeley 94720, USA
    J Neuroimmunol 73:57-62. 1997
  4. ncbi request reprint Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade
    A A Hurwitz
    Cancer Research Laboratory, University of California, Berkeley 94720, USA
    Cancer Res 60:2444-8. 2000
  5. pmc Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy
    A van Elsas
    Howard Hughes Medical Institute and Cancer Research Lab, University of California, Berkeley, CA 94720, USA
    J Exp Med 194:481-9. 2001

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma
    A A Hurwitz
    Howard Hughes Medical Institute, Cancer Research Laboratory, University of California, Berkeley 94720, USA
    Int J Cancer 77:107-13. 1998
    ....
  2. pmc CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
    A A Hurwitz
    Howard Hughes Medical Institute, Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA
    Proc Natl Acad Sci U S A 95:10067-71. 1998
    ..In addition, these results also support the idea that the most effective and synergistic vaccine strategy targets treatments that enhance T cell priming at the level of host-derived antigen-presenting cells...
  3. ncbi request reprint Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis
    A A Hurwitz
    Department of Molecular and Cellular Biology, University of California, Berkeley 94720, USA
    J Neuroimmunol 73:57-62. 1997
    ..These data suggest that CTLA-4-mediated inhibitory signals can regulate the clinical severity and histologic parameters of neuroautoimmune disease...
  4. ncbi request reprint Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade
    A A Hurwitz
    Cancer Research Laboratory, University of California, Berkeley 94720, USA
    Cancer Res 60:2444-8. 2000
    ..These findings demonstrate that this combinatorial treatment can elicit a potent antiprostate response and suggest potential of this approach for treatment of prostate cancer...
  5. pmc Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy
    A van Elsas
    Howard Hughes Medical Institute and Cancer Research Lab, University of California, Berkeley, CA 94720, USA
    J Exp Med 194:481-9. 2001
    ..Our data demonstrate that therapeutic autoreactive CD8(+) T cell responses can effectively be generated in tumor-bearing mice and stresses the value of studying tumor immunity in a therapeutic rather than a prophylactic setting...